Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2025 Rev YoY: -2.8% EPS YoY: -54.9% Move: -0.13%

Previous: Q4 2024 Next: Q2 2025

Revvity Inc

0KHE.L

$99.45 -0.13%

Exchange LSE Sector Healthcare Industry Medical Diagnostics Research

Q1 2025

Published: May 6, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 0KHE.L

Reported

Report Date

May 6, 2025

Quarter Q1 2025

Revenue

664.76M

YoY: -2.8%

EPS

0.34

YoY: -54.9%

Market Move

-0.13%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $664.76M down 2.8% year-over-year
EPS of $0.34 decreased by 54.9% from previous year
Gross margin of 49.2%
Net income of 41.44M
"" -

0KHE.L

Company 0KHE.L

Period Q1 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

Revvity delivered a profitable Q1 2025, but topline momentum cooled against prior year and the prior quarter. Revenue totaled $664.76 million, down 2.82% year-over-year and 8.86% quarter-over-quarter, while gross margin remained robust at 49.2% (gross profit $327.25 million). The company generated $128.16 million of cash from operations and reported free cash flow of $112.17 million, supporting a strong liquidity position as of March 30, 2025. Net income was $41.44 million with an EPS of $0.345, reflecting disciplined cost management in an environment of revenue headwinds. EBITDA stood at $172.77 million with an EBITDA margin of about 26.0%, underscoring earnings quality despite top-line declines.

Key Performance Indicators

Revenue

Decreasing

664.76M

QoQ: -8.86% | YoY: -2.82%

Gross Profit

Decreasing

327.25M

49.23% margin

QoQ: -9.02% | YoY: -14.96%

Operating Income

Decreasing

87.97M

QoQ: -33.50% | YoY: -14.26%

Net Income

Decreasing

41.44M

QoQ: -56.40% | YoY: -55.90%

EPS

Decreasing

0.34

QoQ: -55.78% | YoY: -54.92%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: $664.762 million; YoY change: -2.82%; QoQ change: -8.86%.
Gross Profit: $327.246 million; Gross margin: 49.22%; YoY: -14.96%; QoQ: -9.02%.
Operating Income: $87.971 million; Operating margin: 13.23%; YoY: -14.26%; QoQ: -33.50%.
Net Income: $41.437 million; Net margin: 6.23%; YoY: -55.90%; QoQ: -56.40%.
EPS: $0.3449; Diluted EPS: $0.3446; YoY: -54.92%; QoQ: -55.78%.
EBITDA: $172.768 million; EBITDA margin: 25.99% (EBITDA relative to revenue).
Cash flow: Operating cash flow $128.155 million; Free cash flow $112.173 million.
Balance sheet highlights: Cash and cash equivalents $1.13762 billion; Total assets $12.3607 billion; Total liabilities $4.7236 billion; Total stockholders’ equity $7.6371 billion; Net debt $2.1877 billion; Current ratio 3.58; Quick ratio 2.99; Debt ratio 0.269; Debt/Equity 0.435.
Capital allocation: Share repurchases of $153.594 million; Dividends paid $8.433 million; Net cash used by financing activities $(163.664) million.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	664.76M	-2.82%	-8.86%
Gross Profit	327.25M	-14.96%	-9.02%
Operating Income	87.97M	-14.26%	-33.50%
Net Income	41.44M	-55.90%	-56.40%
EPS	0.34	-54.92%	-55.78%

Key Financial Ratios

Gross Profit Margin

Good

49.20%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Fair

13.20%

Operating margin is moderate, room for improvement in cost management

Net Profit Margin

Fair

6.23%

Net profit margin is moderate, room for improvement in cost management

Return on Assets

Weak

0.34%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.54%

Return on equity suggests inefficient capital allocation

Current Ratio

Strong

3.58

Current ratio indicates excellent liquidity and financial flexibility

Debt to Equity

Moderate

0.44

Debt-to-equity indicates balanced capital structure with manageable debt

P/E Ratio

High Growth

76.69x

Very high P/E indicates aggressive growth expectations, higher risk

Price to Book

Fair Value

1.66x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q4 2025	772.06	0.87	+5.9%	View
Q3 2025	698.95	0.40	-4.2%	View
Q2 2025	720.28	0.47	+5.3%	View
Q1 2025	664.76	0.34	-2.8%	View
Q4 2024	729.37	0.78	+5.5%	View

0KHE.L

Revvity Inc

Q4 2025 Report

Revvity Inc (0KHE.L) QQ4 2025 Results – Revenue Growth, Margin Resilience and Strong Free Cash Flow in Healthcare Diagnostics and Life Sciences...

Read full report

0KHE.L

Revvity Inc

Q3 2025 Report

Revvity Inc (0KHE.L) QQ3 2025 Financial Results – Resilient Diagnostics Leader with Margin Discipline in a Dynamic Healthcare Market...

Read full report

0KHE.L

Revvity Inc

Q2 2025 Report

Revvity Inc (0KHE.L) QQ2 2025 Results Analysis – Resilient Margin Profile, Solid Cash Flow Generation and Moderate Top-Line Growth...

Read full report

0KHE.L

Revvity Inc

Q4 2024 Report

Revvity Inc (0KHE.L) QQ4 2024 Results — Revenue Up 5.5%, Robust Free Cash Flow, and Solid Profitability Amid High Intangibles...

Read full report

Revvity Inc (0KHE.L) Q1 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 0KHE.L Quarterly Reports

0KHE.L

0KHE.L

0KHE.L

0KHE.L

Q1 2025 Reports in Healthcare Sector

0LWG.L

0JT5.L

0HUR.L

Related Financial Data

Sector Analysis: Healthcare

0KHE.L Full Profile

0KHE.L Financial Statements

Earnings Calendar